Color Code
Brown

Controlling Viral Foodborne Disease

635
food
Controlling Viral Foodborne Disease
United States of America
To help CDC collaborate with the U.S. Department of Agriculture and the National Institute of Food and Agriculture to create an integrated, multi-disciplinary approach to developing improved tools, skills and capacity to study foodborne viruses. Outcomes of the partnership will be used to systematically identify risk factors and develop risk management strategies to reduce contamination in pre- and post-harvest environments.
North Carolina State University; United States Department of Agriculture
CDC's National Center for Immunization and Respiratory Diseases

Synthesis of XMRV Peptides

569
lab
Synthesis of XMRV Peptides
United States of America
To develop a mass spectrometry method that can be used to identify and quantify a novel protein produced by the prostate-cancer-associated retrovirus XMRV in patient samples.
Edinburgh Napier University; Emory University School of Medicine; Lypro Biosciences, Inc.; The Children’s Hospital of Philadelphia; University of Maryland Baltimore (National Institutes of Health); University of Louisville; Global Blood Therapeutics
CDC's National Center for Emerging and Zoonotic Infections

Viral Hepatitis Action Coalition

The Viral Hepatitis Action Coalition is a public-private partnership developed by the CDC Foundation to help the Centers for Disease Control and Prevention (CDC) make meaningful advances in the prevention, screening, and treatment of viral hepatitis.

A report on hepatitis and liver cancer issued by The National Academies of Sciences, Engineering and Medicine (formerly the Institute of Medicine (IoM)) in 2010 highlighted an overall lack of knowledge about the extent and seriousness of viral hepatitis in the United States. The report specifically called on CDC to work with public and private partners to:

  • increase data collection on hepatitis B and hepatitis C to provide a better overall understanding of how many people are infected, how they became infected, if and when they got tested and treated, and the outcomes of their treatment; and
  • educate populations at-risk, healthcare providers, and the general public about hepatitis to promote vaccination and prevention strategies and encourage screening and testing

Through the Viral Hepatitis Action Coalition, CDC was able to respond to the urgent calls to action outlined in the 2010 report. Members of the Coalition helped support crucial CDC-led research and programs and amplified CDC’s messages to the public to increase overall awareness of viral hepatitis. From 2010 to 2017, the Coalition successfully facilitated and supported the convening of several meetings, summits, and forums for stakeholders to discuss topics including:

  • CDC’s priorities toward building state and local capacity to prevent viral hepatitis
  • Critical interventions needed to improve the continuum of HCV testing, care, and treatment in the United States
  • U.S. domestic and global topics on prevention and control of viral hepatitis 
  • Stopping the hepatitis C epidemic among young persons who inject drugs

VHACThe final effort that the Coalition lead was convening a public meeting to discuss the National Academies of Science, Engineering, and Medicine expert committee's 2017 report outlining a strategy to eliminate hepatitis B and C as public health problems in the United States. This Hepatitis B and C Elimination Summit cumulated and demonstrated the Coalition’s success in providing a framework to support the initiation of research and program evaluation through partnerships that promote information sharing, stakeholder collaboration, and shared commitment to public health initiatives.

"The Viral Hepatitis Action Coalition has given us capacity that we did not have previously to launch a variety of new projects that our division believes are critically important to our success in preventing disease and deaths from viral hepatitis," says John Ward, Director of CDC’s Division of Viral Hepatitis. 

To learn more about the legacy of the Viral Hepatitis Action Coalition, please contact CDC’s Division of Viral Hepatitis. View a report on the achievements of the Viral Hepatitis Action Coalition.
 

About CDC's Division of Viral Hepatitis

labIn collaboration with domestic and global partners, CDC's Division of Viral Hepatitis (DVH) provides the scientific and programmatic foundation and leadership for the prevention and control of hepatitis virus. DVH conducts research, surveillance, education and training, and evaluation to facilitate policy and design interventions to address the most common forms of viral hepatitis in the United States: hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV). These unrelated viruses are transmitted through different routes and require specific prevention strategies. CDC also conducts surveillance and investigation of other forms of viral hepatitis, particularly those common in other parts of the world, and serves as a WHO Collaborating Center for Reference and Research on Viral Hepatitis.

Learn more: www.cdc.gov/hepatitis

511
Viral Hepatitis Action Coalition
Viral Hepatitis Action Coalition
United States of America
To provide an overall framework for organizations concerned with viral hepatitis to support high priority research, education and program evaluation projects initiated by CDC's Division of Viral Hepatitis.
Abbott Laboratories; AbbVie; Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen Therapeutics; Merck Sharp & Dohme; OraSure Technologies; Quest Diagnostics; Siemens Healthcare Diagnostics; Alere North American, Inc.; Bayer Corporation; Boehringer Ingelheim; Genentech; Gen-Prob, Inc.; GlaxoSmithKline; Kadmon Pharmaceuticals; Onyx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc.
CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; Association of State and Territorial Health Officials (ASTHO); National Viral Hepatitis Roundtable

Treatment of TB with Priftin (rifapentine)

393
TB - CDC image
Treatment of TB with Priftin (rifapentine)
Texas, Colorado, California, Ohio, Washington DC, North Carolina, Tennessee, USA
United States of America
To continue the research and development of the drug Priftin® (rifapentine) and to investigate its role in the treatment of active tuberculosis (TB) disease and latent TB infection.
Sanofi Foundation for North America
CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention

Norovirus In-Vitro Time-Kill Evaluation

401
Norovirus
Norovirus In-Vitro Time-Kill Evaluation
United States of America
To evaluate commercial sanitizing products for their virucidal effectiveness against murine norovirus.
Applied Biocode; Cepheid; Luminex Corporation; Nanosphere, Inc.; R-Biopharm, Inc.
Previous Partners: Arch Chemicals, Inc.; Byotrol; Clemson University; GOJO Industries, Inc.; Holland America Line; IISES, LLC; International Atomic Energy Agency; LigoCyte Pharmaceuticals; Molnlycke Health Care, LLC; Oxoid Ltd.; Pathcon Laboratories; Proctor & Gamble Company; Radco Chemical Solution; Remel, Inc.; Takeda Pharmaceuticals; University of Queensland; Therapeutic Goods; University of North Carolina
CDC's National Center for Immunization and Respiratory Diseases

Improving Pneumococcal Vaccine

659
vaccine
Improving Pneumococcal Vaccine
United States of America
To compare the immunogenicity of current vaccines for pneumococcal disease (native pneumococcal polysaccharide vaccine) with a proposed new vaccination method (microsphere entrapped pneumococcal capsular polysaccharides delivered either subcutaneously or intranasally).
Georgia Research Alliance
CDC's National Center for Immunization and Respiratory Diseases; Emory University; Mercer University

Preventing Infections in Cancer Patients

Through a CDC Foundation collaboration with Amgen, CDC is leading a comprehensive program focused on providing information, action steps and tools for patients, their families, and their healthcare providers to reduce the risk of developing potentially life-threatening infections during chemotherapy treatment.

One of the most common and potentially life-threatening side effects of chemotherapy is neutropenia and the subsequent development of infections. Infections in cancer patients undergoing chemotherapy may lead to hospitalization, disruptions in chemotherapy schedules, and in some cases, can be life threatening. Each year, an estimated 60,000 patients are hospitalized for chemotherapy-induced neutropenia, and a patient dies every two hours from this complication. The sources of these infections can be through patient interactions with family and social networks or from healthcare settings.

Through this collaboration, CDC developed a comprehensive campaign focused on preventing infections in cancer patients by targeting patients, their families, and their healthcare providers. For patients, CDC developed an interactive website, 3 Steps Toward Preventing Infections During Cancer Treatment. 3 Steps is an interactive online education program that provides individually tailored information to help patients recognize the signs and symptoms of infection and implement measures to prevent and control those infections.

For providers, CDC experts developed a Basic Infection Control and Prevention Plan for Outpatient Oncology Settings that outlines infection control policies and procedures—injection safety, hand hygiene, environmental disinfection, etc.—that can be tailored to any oncology clinic.

CDC also produced a collection of materials, like posters for oncology clinics, patient brochures and fact sheets, to support campaign messages. The materials are available online at www.cdc.gov/cancer/preventinfections.

David Reese is vice president of Translational Sciences for Amgen, a biotechnology company that develops medicines to help fight cancer, kidney disease, rheumatoid arthritis and other serious illnesses. “Partnering with the CDC Foundation has provided a great opportunity for Amgen to work with the experts at CDC to provide information and tools to help reduce infections in cancer patients,” said Reese. “We’re proud of this multi-year collaboration, which has been a perfect opportunity for two organizations with similar expertise to join forces and leverage each other’s strengths for the benefit of patients.”

Learn More

Healthcare-associated Infections (HAI)
on the CDC website

485
preventing infections in cancer patients
Preventing Infections in Cancer Patients
United States of America
To develop a comprehensive education campaign targeting cancer patients, their families and their providers to reduce the risk of infection in multiple settings (outpatient office, hospital and home).
Amgen
CDC's National Center for Chronic Disease Prevention and Health Promotion; CDC’s National Center for Emerging and Zoonotic Infectious Diseases; Medscape; WebMD Health Corporation

Prevent Antimicrobial Resistance in Healthcare Setting

190
safe healthcare
Prevent Antimicrobial Resistance in Healthcare Setting
United States of America
To develop a series of health communications aimed at increasing awareness among physicians of CDC's goals of preventing the spread of antimicrobial resistance. The goal of this initiative is to develop an integrated program to prevent emergence and spread of antimicrobial-resistant infections among patients in healthcare settings.
BD (Beckton, Dickinson and Company); Cubist Pharmaceuticals (now Merck); Kimberly-Clark USA; Merck Sharp & Dohme Corp.; Ortho-McNeil Pharmaceutical, Inc.; Premier, Inc.; University of Alabama at Birmingham; Vermont Oxford Network, Inc.; Wellpoint Foundation
CDC's National Center for Emerging and Zoonotic Infectious Diseases

Safe Injection Practices Coalition

459/772
safe injection practices
Safe Injection Practices Coalition
District of Columbia, Georgia, Illinois, Nebraska, Nevada, Virginia, USA
United States of America
To promote safe injection practices in all U.S. healthcare settings, the Safe Injection Practices Coalition is a partnership of healthcare-related organizations, patient advocacy organizations, industry partners and other public health partners, led by CDC. The Coalition has developed the One & Only Campaign – a public health education and awareness campaign aimed at both healthcare providers and patients to advance and promote safe injection practices.
Eli Lilly and Company
CDC’s National Center for Emerging and Zoonotic Infectious Diseases; Accreditation Association for Ambulatory Health Care, Inc. (AAAHC); American Association of Nurse Anesthetists (AANA); Association for Professionals in Infection Control and Epidemiology, Inc. (APIC); American Society for Healthcare Risk Management (ASHRM); Association of State and Territorial Health Officials (ASTHO); Eli Lilly and Company; HONOReform Foundation; Institute for Safe Medication Practices (ISMP); National Association of County & City Health Officials (NACCHO); Premier Safety Institute; Society of Gastroenterology Nurses and Associates (SGNA); The Society for Healthcare Epidemiology of America (SHEA); U.S. Food and Drug Administration – Safe Use Initiative (Advisor)
Subscribe to Infectious Disease